Increased chemical purity using a hydrate

被引：22

作者：

Black, SN ^{[1
]}

Cuthbert, MW

Roberts, RJ

Stensland, B

机构：

[1] AstraZeneca, Macclesfield SK10 2NA, Cheshire, England

[2] AstraZeneca, S-15185 Sodertalje, Sweden

来源：

CRYSTAL GROWTH & DESIGN | 2004年 / 4卷 / 03期

关键词：

D O I：

10.1021/cg034222v

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Crystallization is usually a highly selective process, and this selectivity is exploited in the pharmaceutical and other industries as a method of chemical purification. Relatively little is known about how polymorphism and solvate formation can influence the selectivity of crystallizations. We describe a piperidene pharmaceutical intermediate that can crystallize as either a hydrate or an anhydrous form, with very different purities. The exploitation of this effect is described, and an explanation in terms of the crystal structures is proposed.

引用

页码：539 / 544

页数：6

共 10 条

[1]

Bernstein J., 2020, Polymorphism in Molecular Crystals, Vsecond

[2]

Byrn S.R., 1999, Solid State Chemistry of Drugs, VSecond

[3] Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development [J].